viewSynairgen PLC

Synairgen gets green light for home study of coronavirus inhaled drug; top line data expected in July

The idea is to treat sufferers earlier in the illness – within three days of developing symptoms

Synairgen PLC -

Synairgen PLC (LON:SNG) has confirmed the launch of the clinical trial in a home setting of its inhaled interferon-beta-1a on people with coronavirus (COVID-19).

An expansion of the original hospital-based SG016 study, an extra 120 people will receive Synairgen’s SNG001 medication at their homes.

The idea is to treat sufferers earlier in the illness – within three days of developing symptoms.

The launch of the expansion phase follows the receipt of the “necessary approvals”.

A total of 98 of the original 100 hospital cohort has now been dosed, according to Synairgen chief executive Richard Marsden, who expects to announce top-line data from the trial in July.

“If successful, we would hope to protect the lungs and prevent the development of the severe lower respiratory tract illness which puts the healthcare system under such strain,” he added in a statement.

Nick Francis, professor of general practice at the University of Southampton, said there was a “desperate need” for a coronavirus treatment that can be administered during the early phase of the illness to prevent the progression of severe symptoms.

"This novel trial approach is essential for the ongoing health of those at higher risk because of increasing age or other risk factors,” he added.

“The approach could be rolled out across many areas of primary care involving the interaction with vulnerable patients, including the elderly if it is successful.”

  • In a separate announcement, Synairgen released its results for the year to December 31. As is standard with a firm involved in research and development, it was lossmaking –  to the tune of £4.82mln. R&D expenditure was £3.46mln. While cash at the year-end was £2.45mln, the company raised £14mln in March in an oversubscribed share issue.

Quick facts: Synairgen PLC

Price: 37.188 GBX

Market: AIM
Market Cap: £55.57 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Synairgen PLC named herein, including the promotion by the Company of Synairgen PLC in any Content on the Site, the Company receives from said...



Synairgen PLC pleased with further positive data from lead COPD drug

Richard Marsden, chief executive of Synairgen plc (LON:SYN), tells Proactive's Andrew Scott data from the ongoing phase II study of their SNG001 drug suggests it's having the desired effect in boosting the antiviral defences of chronic obstructive pulmonary disease (COPD)...

on 28/6/18

2 min read